Navigation Links
AAOMS Updates BRONJ Position Paper
Date:1/22/2009

ROSEMONT, Ill., Jan. 22 /PRNewswire-USNewswire/ -- The American Association of Oral and Maxillofacial Surgeons has revised its 2006 landmark position paper on Bisphosphonate-Related Osteonecrosis of the Jaw to reflect the most current research and thought on this condition. BRONJ appears as a non-healing exposed bone in the maxillofacial region and may affect patients undergoing intravenous cancer-related bisphosphonate therapy or more rarely, patients treated with oral or IV bisphosphonates for osteoporosis.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050125/CGTU021LOGO)

Written by the members of the distinguished AAOMS Task Force on BRONJ who prepared the original paper, the 2009 BRONJ Position Paper updates the staging and management strategies for BRONJ, and highlights the status of basic science research relating to this condition.

The 2009 Position Paper retains the case definition of BRONJ:

1. The patient is or has been treated with a bisphosphonate.

2. Exposed bone has been present in the maxillofacial region for more than eight weeks; and

3. There is no history of radiation therapy to the jaws.

While there is strong evidence supporting an association between IV bisphosphonate therapy for cancer-related conditions and BRONJ, the 2009 BRONJ Position Paper stresses that the relationship between oral or IV bisphosphonates for treating osteoporosis and BRONJ is more difficult to establish.

Specifically, the 2009 BRONJ Position Paper observes that the risk of developing BRONJ is linked to:

1. The potency the bisphosphonate used in therapy; and

2. The length of exposure to bisphosphonates.

Other factors that may increase the risk of developing BRONJ include:

  • A history of inflammatory dental disease, such as periodontal disease and dental abscesses;
  • Increased age;
  • Other systemic factors or conditions, such as renal dialysis, low hemoglobin, obesity and diabetes; and
  • In some cases, there may be a genetic predisposition to developing BRONJ.

The 2009 BRONJ Position Paper offers some strategies for preventing BRONJ in cancer patients treated with IV bisphosphonates.

  • Prior to initiation of cancer-related IV bisphosphonate treatment, patients should have a thorough dental examination and complete the necessary procedures to achieve optimal periodontal health.
  • Given the long-term biologic activity of IV bisphosphonates noted in the literature, the 2009 Position Paper suggests that alternative dosing regimens that reduce bisphosphonate exposure may be effective in decreasing the risk for BRONJ.

Changes to the staging system include the addition of Stage 0, which includes patients exposed to bisphosphonates and who present with non-specific symptoms, or clinical and radiographic abnormalities.

BRONJ is painful and difficult to treat. While osteonecrosis of the jaw has been recognized by dental and medical practitioners for many years, the identification of bisphosphonates as a contributory factor to the condition was first reported by oral and maxillofacial surgeons about five years ago when they noticed an increase in the number of patients exhibiting the signs of ONJ. A review of these cases indicated that bisphosphonate therapy was a common thread.

In 2006, the American Association of Oral and Maxillofacial Surgeons appointed the Task Force on BRONJ to review the existing literature and prepare a position paper that synthesized the findings for the dental and medical communities.

In late 2008, the Task Force on BRONJ was reconstituted to review the research conducted in the intervening two years. The 2009 BRONJ Position Paper is the result of their efforts.

The complete 2009 BRONJ Position Paper is available at aaoms.org

(http://www.aaoms.org/docs/position_papers/bronj_update.pdf).

Saving Faces, Changing Lives -- The American Association of Oral and Maxillofacial Surgeons (AAOMS), the professional organization representing more than 8,500 oral and maxillofacial surgeons in the United States, supports its fellows' and members' ability to practice their specialty through education, research and advocacy. AAOMS fellows and members comply with rigorous continuing education requirements and submit to periodic office examinations, ensuring the public that all office procedures and personnel meet stringent national standards.


'/>"/>
SOURCE American Association of Oral & Maxillofacial Surgeons
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
2. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
3. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
4. Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
5. Genmab Announces Updates on Phase III Cancer Studies
6. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
7. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
8. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
9. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
10. BioCryst Updates Peramivir Clinical Development Plan
11. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... 23, 2016 Gamida Cell, a ... of cancer and orphan genetic diseases, announced today it ... million from the Israel Innovation Authority (formerly the Office ... Economy and Industry. The mission of the Israel Innovation ... industries, including science and technology, while stimulating economic growth. ...
(Date:5/22/2016)... 2016 DS Biopharma (DS) ... anti-inflammatory compound DS102 in chronic obstructive pulmonary disease ... (NASH) patients. Recent DS preclinical data ... tissue and has bronchodilatory, anti-inflammatory and anti-fibrotic properties ... Company will publish further detail on these findings ...
(Date:5/20/2016)... 2016 - Revenue Forecasts ... Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine ... New Study Reveals Selling Opportunities and Revenue Prospects ... ,What is the future of biologics, especially new ... commercial analysis. Staying ahead in data and knowledge, ...
Breaking Medicine Technology:
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... Researchers can ... so routine. A fresh look at this technique may yield big benefits. Scientists ... reproducibility of experiments in a cell culture laboratory—and lessen the risk of contamination ...
(Date:5/23/2016)... ... May 23, 2016 , ... In light of ... reminds pet owners that intervening at the first sign of their pet overheating ... normal body mechanisms cannot keep the body’s temperature within a safe range. Considered ...
(Date:5/23/2016)... ... May 23, 2016 , ... The Society for Women’s Health ... to move on from that role. , “No one in Washington led the way ... said SWHR Founder Florence Haseltine, MD, PhD. “We offer our deep gratitude to Phyllis ...
(Date:5/23/2016)... ... 2016 , ... Hadley Institute for the Blind and Visually ... or visually impaired, announces the election of Julie S. Tye as its next ... of Trustees retained Morris & Berger, a firm specializing in non-profit executive searches, ...
(Date:5/23/2016)... NY (PRWEB) , ... May 23, 2016 , ... ... the company’s top management team to meet the needs of its recent and ... to drive continued growth and business development across widening market segments. Max joined ...
Breaking Medicine News(10 mins):